VNDA Share Price

Open 15.20 Change Price %
High 15.45 1 Day -0.05 -0.33
Low 15.15 1 Week 0.75 5.19
Close 15.20 1 Month 0.95 6.67
Volume 485355 1 Year 6.04 65.94
52 Week High 18.00
52 Week Low 8.04
VNDA Important Levels
Resistance 2 15.48
Resistance 1 15.36
Pivot 15.27
Support 1 15.04
Support 2 14.92
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
SIRI 5.02 -1.76%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 37.43 1.35%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
IFON 0.63 34.04%
WRES 0.09 28.57%
SMSI 1.13 28.41%
EXAS 30.14 26.64%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPHC 2.80 21.21%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SNCR 13.29 -46.02%
DVOX 0.05 -44.44%
More..

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

VNDA Technical Analysis 4
As on 27th Apr 2017 VNDA Share Price closed @ 15.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 14.13 & Strong Buy for SHORT-TERM with Stoploss of 14.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
VNDA Target for April
1st Target up-side 15.02
2nd Target up-side 15.74
3rd Target up-side 16.46
1st Target down-side 12.98
2nd Target down-side 12.26
3rd Target down-side 11.54
VNDA Other Details
Segment EQ
Market Capital 96253192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vandapharmaceuticals.com
VNDA Address
VNDA
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
Phone: 202-734-3400
Fax: 202-296-1450
Interactive Technical Analysis Chart Vanda Pharmaceuticals Inc. ( VNDA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vanda Pharmaceuticals Inc.
VNDA Business Profile
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.